Targeted Alpha News Today

SYDNEY--(BUSINESS WIRE)--#CMO--AdvanCell, a clinical-stage radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for patients with cancer, today announced the appointment of

PARIS--(BUSINESS WIRE)--Regulatory News:Orano Med (Orano group subsidiary), a leading innovator in the field of Targeted Alpha Therapies in oncology, is thrilled to announce the appointment of Dr. Volker Wagner MD PhD as its new Chief Medical Officer. Dr. Wagner brings a wealth of experience and expertise to the rol...

AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with 212Pb-ADVC001, a Targeted Alpha Therapy in development for the treatment of PSMA-positive metastatic Castration-Resistant Prostate Cancer (mCRPC).

SYDNEY--(BUSINESS WIRE)--AdvanCell, a radiopharmaceutical company developing a pipeline of Targeted Alpha Therapies for cancer patients, today announced the first patient was treated with

Series B financing will accelerate growth and advance lead clinical program 212Pb-ADVC001 a best-in-class treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress

A team of scientists from Preston have made a breakthrough in producing lifesaving cancer treatment known as Lead-212

/PRNewswire/ -- Nihon Medi-Physics Co., Ltd. (NMP), a leading radiopharmaceutical company in Japan, announced on April 5, 2022, that the company has...

Telix Pharmaceuticals (ASX:TLX) has raised $175 million it says will be used to fund the progression of its promising pipeline. The company is focused

The Telix Pharmaceuticals (ASX: TLX) share price is tumbling amid the release of the company's December quarter results and a capital raise.

Interview with Philippe Knoche, Chief Executive Officer of Orano